Popular Articles
Natural Remedies

Addex Partner Starts First-Ever Clinical Trial Of An MGluR Positive Allosteric Modulator
Allosteric modulation company Addex Pharmaceuticals (SWISS: ADXN) announced today that its partner Ortho-McNeil- Janssen Pharmaceuticals Inc. (OMP) has started Phase I testing of ADX71149, a metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM). This product, which has potential to treat schizophrenia, anxiety, depression and other CNS disorders, is the first PAM of any mGluR subtype to enter clinical trials. Targeting mGluR2 with a PAM is a novel approach that may offer advantages over classical drug approaches. In reaching this milestone, Addex received a EUR 1 million payment from OMP and remains eligible for additional development milestones and royalties.
generic viagra online
Lawsuits Allege Some Medical Device Companies Gave Kickbacks To Surgeons
Whistleblowers allege in lawsuits unsealed Wednesday that some medical device companies gave kickbacks to heart surgeons to get the doctors to use their products to treat a heart condition, The Wall Street Journal reports.
News of the day
Identification Of Potential Risks Of Therapies Taken By The Elderly
Researchers unveiled data during Digestive Disease Week® (DDW®) 2009 examining the potential risks associated with two commonly-used treatments, particularly among the elderly: acid suppressors and antithrombotics. DDW is the largest international gathering of physicians and researchers in the field of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
Medical Devices

Diabetes Is Significant Economic Burden For US Health-Care System

Excess medical expenses and reduced productivity due to diabetes costs the U.S. economy more than $174 billion annually, a figure that could be reduced by lifestyle modifications and preventive care and by pay-for-performance incentives that reward improved disease management, as supported by three articles in the recent issue of Population Health Management, a peer-reviewed journal published by Mary Ann Liebert, Inc.. These diabetes-related reports are available free online here. Three timely articles examine the challenges presented by the rising number of Americans with diabetes. The reports estimate the national medical costs associated with caring for adults with prediabetes or gestational diabetes and present a critical analysis of a pay-for-performance incentive to improve the care of patients with diabetes. "This research adds significant new information to our understanding of the total burden diabetes mellitus puts on our society," says Journal Editor-in-Chief David B. Nash, MD, MBA, Dean, and Dr. Raymond C. and Doris N. Grandon Professor, Jefferson School of Population Health (Philadelphia, PA). The article entitled "Medical Cost Associated with Prediabetes" showed that in 2007, care for these patients was more than $25 billion, or an additional $443 for each adult compared to individuals with normal blood sugar levels, according to a study by Yiduo Zhang, PhD, and colleagues from the Lewin Group (Falls Church, VA) and Ingenix/i3research (Basking Ridge, NJ and Nanterre, France). The authors conclude that these findings "strengthen the business case for lifestyle interventions to prevent diabetes by adding additional economic benefits that potentially can be achieved by preventing or delaying PD." Excessive use of medical services by adults with diabetes could be reduced by better adherence by physicians to evidence-based clinical guidelines intended to improve diabetes care. Thomas Foels, MD, and Sharon Hewner, RN, PhD, from Independent Health Association (Buffalo, NY), report on a study targeting adult primary care physicians and encouraging consistent adherence to guidelines, a critical review of practice patterns related to care of diabetic patients, and changes in office systems to improve care. In "Integrating Pay for Performance with Educational Strategies to Improve Diabetes Care," the authors demonstrate that participation- and performance-based economic incentives can yield significant improvements in adherence to diabetes clinical guidelines, office-based education, and overall disease management. Yaozhu Chen, MPA, and co-authors from The Lewin Group (Falls Church, VA), Ingenix/i3research (Basking Ridge, NJ), and Ingenix/i3 Pharmainformatics (Cary, NC), estimate the "Cost of Gestational Diabetes Mellitus in the United States in 2007" at an additional $3,305 per pregnancy, plus $209 during an infant"s first year of life. In 2007, for the estimated 180,000 pregnancies affected by gestational diabetes, the total national medical costs were $636 million. Amy Gleason Quarshie Mary Ann Liebert, Inc./Genetic Engineering News


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):